1.Alternative Name:TNFRSF7,Tp55；CD27 antigen; CD27 molecule; CD27; MGC20393; S152CD27L receptor; T cell activation antigen CD27; T cell activation antigen S152; T14; TNFRSF7; TNFRSF7T-cell activation antigen CD27; Tp55; Tumor necrosis factor receptor superfamily member 7; tumor necrosis factor receptor superfamily, member 7
2.Target:CD27
3.Source:Human CD27 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Thr21-Ile192
5.Protein structure:P26842hFC
6.Molecular Characterization:The protein has a calculated MW of 45kDa.The reducing (R) heterodimer protein migrates as 50-90 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .


11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.ELISA

When Recombinant Human CD27/ hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD27 (Varlilumab) that produces 50% of the optimal binding response is approximately 20 ng/ml.